sellWeak cluster of 510b5-1 plan
Andrew Cheng sold $1.4M of AKRO
President and CEO at Akero Therapeutics, Inc.. 31,796 shares at an average of $43.23, traded Sep 10, 2025, filed Sep 12, 2025.
Warning score
30Value
$1.4M
31,796 shares
Holdings after
473,902
-6% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$1.4M at market
- 0Share of holdings soldSold 6.3% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-114661, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 10, 2025 | MOption exercise Common Stock10b5-1 | +13,022 | $6.36 | $83k | 503,779 | Sep 12, 2025 |
| Sep 10, 2025 | MOption exercise Common Stock10b5-1 | +1,919 | $19.87 | $38k | 505,698 | Sep 12, 2025 |
| Sep 10, 2025 | SOpen-market sale Common Stock10b5-1 | -22,525 | $42.99 | $968k | 483,173 | Sep 12, 2025 |
| Sep 10, 2025 | SOpen-market sale Common Stock10b5-1 | -7,317 | $44.00 | $322k | 475,856 | Sep 12, 2025 |
| Sep 10, 2025 | SOpen-market sale Common Stock10b5-1 | -158 | $44.62 | $7,050 | 475,698 | Sep 12, 2025 |
| Sep 11, 2025 | SOpen-market sale Common Stock10b5-1 | -1,796 | $43.02 | $77k | 473,902 | Sep 12, 2025 |
| Sep 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -13,022 | $0.00 | $0 | 0 | Sep 12, 2025 |
| Sep 10, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,919 | $0.00 | $0 | 410,017 | Sep 12, 2025 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.6M 30,000 shares | -5% | |
| 14Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $576k 12,500 shares | -7% | |
| 19Weak | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $597k 12,500 shares | -6% | |
| 30Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $24k 553 shares | -0% | |
| 42Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $28k 659 shares | -1% | |
| 35Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $28k 659 shares | -1% | |
| 40Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $25k 586 shares | -0% | |
| 14Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $552k 12,500 shares | -7% | |
| 19Weak | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $576k 12,500 shares | -6% | |
| 45Moderate | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.5M 30,000 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.